Literature DB >> 23246163

Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine.

Pavan Kumar Bhamidipati1, Elias Jabbour, Sergej Konoplev, Zeev Estrov, Jorge Cortes, Naval Daver.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23246163      PMCID： PMC4019340          DOI： 10.1016/j.clml.2012.10.002

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  28 in total

1.  Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells.

Authors:  K Lotfi; E Månsson; T Spasokoukotskaja; B Pettersson; J Liliemark; C Peterson; S Eriksson; F Albertioni
Journal:  Clin Cancer Res       Date:  1999-09       Impact factor: 12.531

2.  A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.

Authors:  Susan P Perrine; Olivier Hermine; Trudy Small; Felipe Suarez; Richard O'Reilly; Farid Boulad; Joyce Fingeroth; Melissa Askin; Arthur Levy; Steven J Mentzer; Massimo Di Nicola; Alessandro M Gianni; Christoph Klein; Steven Horwitz; Douglas V Faller
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

3.  Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.

Authors:  Sima Jeha; Paul S Gaynon; Bassem I Razzouk; Janet Franklin; Richard Kadota; Violet Shen; Lori Luchtman-Jones; Michael Rytting; Lisa R Bomgaars; Susan Rheingold; Kim Ritchey; Edythe Albano; Robert J Arceci; Stewart Goldman; Timothy Griffin; Arnold Altman; Bruce Gordon; Laurel Steinherz; Steven Weitman; Peter Steinherz
Journal:  J Clin Oncol       Date:  2006-04-20       Impact factor: 44.544

Review 4.  EBV-associated lymphoproliferative disorders: classification and treatment.

Authors:  Antonino Carbone; Annunziata Gloghini; Giampietro Dotti
Journal:  Oncologist       Date:  2008-05

5.  What is the optimal treatment for biphenotypic acute leukemia?

Authors:  Changcheng Zheng; Jingsheng Wu; Xin Liu; Kaiyang Ding; Xiaoyan Cai; Weibo Zhu
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

6.  Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.

Authors:  Stefan Faderl; Srdan Verstovsek; Jorge Cortes; Farhad Ravandi; Miloslav Beran; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Susan O'Brien; Charles Koller; Francis J Giles; William Wierda; Monica Kwari; Hagop M Kantarjian
Journal:  Blood       Date:  2006-01-10       Impact factor: 22.113

7.  Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.

Authors:  R Khanna; S Bell; M Sherritt; A Galbraith; S R Burrows; L Rafter; B Clarke; R Slaughter; M C Falk; J Douglass; T Williams; S L Elliott; D J Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

8.  A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Authors:  Stefan Faderl; Farhad Ravandi; Xuelin Huang; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Gautam Borthakur; Srdan Verstovsek; Deborah A Thomas; Monica Kwari; Hagop M Kantarjian
Journal:  Blood       Date:  2008-06-18       Impact factor: 22.113

9.  Clinical characteristics and outcome of children with biphenotypic acute leukemia.

Authors:  Amal S Al-Seraihy; Tarek M Owaidah; Mouhab Ayas; Hassan El-Solh; Mohammed Al-Mahr; Ali Al-Ahmari; Asim F Belgaumi
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

10.  Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital.

Authors:  Jeffrey E Rubnitz; Mihaela Onciu; Stanley Pounds; Sheila Shurtleff; Xueyuan Cao; Susana C Raimondi; Frederick G Behm; Dario Campana; Bassem I Razzouk; Raul C Ribeiro; James R Downing; Ching-Hon Pui
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113
View more
  1 in total

Review 1.  EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management.

Authors:  Chi Young Ok; Ling Li; Ken H Young
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.